KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Capital Leases (2021 - 2025)

Bionano Genomics' Capital Leases history spans 5 years, with the latest figure at $3.5 million for Q3 2025.

  • For Q3 2025, Capital Leases fell 1.58% year-over-year to $3.5 million; the TTM value through Sep 2025 reached $3.5 million, down 1.58%, while the annual FY2024 figure was $3.5 million, 1.28% down from the prior year.
  • Capital Leases for Q3 2025 was $3.5 million at Bionano Genomics, roughly flat from $3.5 million in the prior quarter.
  • Across five years, Capital Leases topped out at $3.6 million in Q4 2021 and bottomed at $3.5 million in Q3 2025.
  • The 5-year median for Capital Leases is $3.6 million (2023), against an average of $3.6 million.
  • The largest annual shift saw Capital Leases decreased 0.63% in 2022 before it fell 1.58% in 2025.
  • A 5-year view of Capital Leases shows it stood at $3.6 million in 2021, then fell by 0.63% to $3.6 million in 2022, then dropped by 0.94% to $3.6 million in 2023, then dropped by 1.28% to $3.5 million in 2024, then fell by 1.24% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Capital Leases are $3.5 million (Q3 2025), $3.5 million (Q2 2025), and $3.5 million (Q1 2025).